Mana.bio, a Tel Aviv, Israel-based biotechnology company accelerating programmable drug delivery, raised $19.5M in seed financing.
The round was co-led by Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird and Technion Institute of Technology.
Led by Yogev Debbi, co-founder and CEO, Roy Nevo, co-founder and CTO, Avi Schroeder, PhD, scientific co-founder, and Kira Radinsky, PhD, scientific co-founder, Mana.bio provides an AI platform that discovers and optimizes novel, customizable LNPs for tissue-specific delivery of nucleic acid-based therapeutics and vaccines. Its AI-based lipid nanoparticle (LNP)
The company intends to use the funds to advance development of its proprietary, purpose-built AI LNP platform to deliver RNA and gene therapies to specific extrahepatic tissues in the body.
FinSMEs
13/10/2023